Triple Therapy in Type 1 Diabetes Improves Glycemic Control but Carries Ketosis Risks (FREE)
By Amy Orciari Herman
Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS
Adding dapagliflozin to liraglutide and insulin in patients with type 1 diabetes lowers hemoglobin A1c levels but poses risk for ketoacidosis, …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news
More News: Dapagliflozin | Diabetes | Diabetes Type 1 | Endocrinology | Forxiga | Insulin | Primary Care | Victoza